Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

Exclusion Criteria

• •Current concomitant presence of other malignancies within 5 years prior to the first dose；
• •At the time of initiating the study of treatment, the adverse reactions caused by previous anti-tumor treatments failed to recover to a CTCAE 5.0 score of grade 1 or below.
• •Patients who had received major surgical treatment within 4 weeks prior to the first study, had obvious traumatic injuries, or were expected to undergo major surgery during the study treatment period, or had long-term unhealed wounds or fractures.
• •Hyperactive or venous thrombosis events occurred within 6 months before the first administration;
• •Major cardiovascular diseases;
• •Active hepatitis
• •Those with a history of psychotropic drug abuse who are unable to quit or have mental disorders.
• •There was an active infection (≥ Common Terminology Criteria for Adverse Events version 5.0 (CTCAE5.0) score of grade 2) within 2 weeks before the first administration;
• •Patients with renal failure requiring hemodialysis or peritoneal dialysis;
• •Patients who have a history of immune deficiency.
• •Patients who have epilepsy and need treatment;
• •Evidence of a previous history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any clinically active interstitial lung disease.
• •Those who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first treatment.
• •Pregnant or lactating women.
• •There is any serious or uncontrolled systemic disease.